Enhanced antitumor immune responses via a new agent [ 131 I]-labeled dual-target immunosuppressant.

Chunjuan JiangQiwei TianXiaoping XuPanli LiSimin HeJian ChenBolin YaoJianping ZhangZiyi YangShaoli Song

Published in: European journal of nuclear medicine and molecular imaging (2022)

I] combined with a dual-target immunosuppressant could be exploited to identify the subset of treatment responders but also exhibited great potential for enhancing antitumor immune responses.

Keyphrases

immune response
toll like receptor
dendritic cells
computed tomography
replacement therapy